Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without ipilimumab versus placebo maintenance after first-line chemotherapy in extensive-stage small cell lung cancer
2015-002441-61Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Nivolumab monotherapy maintenance, Nivolumab plus ipilimumab followed by nivolumab and Placebo maintenance (3 arms). Primary endpoint: Overall survival. Started Dec 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-002441-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002441-61.